BioSpace News Archive

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on July 5, 2023, to all shareholders of record as of June 15, 2023.

SomaLogic, Inc., a leader in proteomics technology, announced that the company will be participating in the upcoming Jefferies Healthcare Conference.

Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced a leadership change.

Hepion Pharmaceuticals, Inc. announces that its Senior Vice President for Clinical Pharmacology and Analytics, Patrick Mayo, PhD, and its Quantitative Systems Pharmacologist, Caroline Zhao, PharmD, will present at the 2023 Canadian Society for Pharmaceutical Sciences Annual Symposium being held in Toronto, Canada from May 24 to May 26, 2023.

Carina Biotech, a cell therapy immuno-oncology company, announced that the management team will participate in the three upcoming conferences as follows:

Aligos Therapeutics, Inc. announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. ET.

Stevanato Group S.p.A., a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced that it will participate in two upcoming investor conferences.

Aura Biosciences Inc. announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: TD Cowen 4th Annual Oncology Innovation Summit on Tuesday, May 30, 2023.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 53,800 shares of the Company’s common stock at an exercise price per share of $18.05, which was the closing price on May 23, 2023, and restricted stock units to acquire a total of 26,900 shares of the Company’s common stock.

CytoDyn Inc., a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that Dr. Cyrus Arman, the Company’s President, has taken a medical leave of absence.